drugset
drugset / Trial / NCT05225389

Study to Assess the Absorption, Metabolism, Excretion, and Mass Balance of CT1812 in Healthy Adult Male Subjects

NCT05225389 ↗

Phase 1 Completed 8 enrolled Cognition Therapeutics National Institute on Aging (NIA) · collab
NaSingle-groupOpen-labelBasic science

Summary

Open-label, single-dose study to assess the absorption, metabolism, excretion and mass balance of \[C14\] CT1812

Timeline

Start
2021-12-31
Primary completion
2022-01-17
Completion
2022-01-24

Drugs

EvaluationDrugModalityDoseRoute
Subject CT1812 Small molecule 300 mg Oral

Indications

Alzheimer disease